[
    [
        {
            "time": "2019-03-26",
            "orginal_text": "上调评级至买入策略选股（3月26日）",
            "features": {
                "keywords": [
                    "药明康德",
                    "评级",
                    "买入"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "上调评级至买入策略选股（3月26日）",
            "scores": {
                "News_content": "上调评级至买入策略选股（3月26日）",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-03-26",
            "orginal_text": "药明康德2019归母净利润降17.96% 毛利率同比下滑 盈利能力下降",
            "features": {
                "keywords": [
                    "药明康德",
                    "净利润",
                    "毛利率",
                    "盈利能力",
                    "下降"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "药明康德2019归母净利润降17.96% 毛利率同比下滑 盈利能力下降",
            "scores": {
                "News_content": "药明康德2019归母净利润降17.96% 毛利率同比下滑 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-26",
            "orginal_text": "药明康德2019年净利下滑18% 拟定增募资不超65.28亿元 盈利能力下降",
            "features": {
                "keywords": [
                    "药明康德",
                    "净利",
                    "下滑",
                    "募资",
                    "盈利能力",
                    "下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "药明康德2019年净利下滑18% 拟定增募资不超65.28亿元 盈利能力下降",
            "scores": {
                "News_content": "药明康德2019年净利下滑18% 拟定增募资不超65.28亿元 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-26",
            "orginal_text": "药明康德业绩受非主业影响大 募资65亿投入生产研发",
            "features": {
                "keywords": [
                    "药明康德",
                    "业绩",
                    "非主业",
                    "募资",
                    "生产研发"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "药明康德业绩受非主业影响大 募资65亿投入生产研发",
            "scores": {
                "News_content": "药明康德业绩受非主业影响大 募资65亿投入生产研发",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-26",
            "orginal_text": "药明康德：全方位一体化赋能客户 业务保持强劲发展势头",
            "features": {
                "keywords": [
                    "药明康德",
                    "一体化",
                    "赋能",
                    "业务",
                    "发展势头"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "药明康德：全方位一体化赋能客户 业务保持强劲发展势头",
            "scores": {
                "News_content": "药明康德：全方位一体化赋能客户 业务保持强劲发展势头",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-26",
            "orginal_text": "药明康德：BCP业务连续性计划保障业务健康发展",
            "features": {
                "keywords": [
                    "药明康德",
                    "BCP",
                    "业务连续性",
                    "健康发展"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "药明康德：BCP业务连续性计划保障业务健康发展",
            "scores": {
                "News_content": "药明康德：BCP业务连续性计划保障业务健康发展",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-26",
            "orginal_text": "犀牛财经早报：苹果或推迟5G手机发布 药明康德2019净利降17.96% 盈利能力下降",
            "features": {
                "keywords": [
                    "药明康德",
                    "净利",
                    "下降",
                    "盈利能力"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "犀牛财经早报：苹果或推迟5G手机发布 药明康德2019净利降17.96% 盈利能力下降",
            "scores": {
                "News_content": "犀牛财经早报：苹果或推迟5G手机发布 药明康德2019净利降17.96% 盈利能力下降",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-26",
            "orginal_text": "疫情“次生”影响：按下了暂停键的临床试验和CDMO行业",
            "features": {
                "keywords": [
                    "疫情",
                    "次生影响",
                    "临床试验",
                    "CDMO"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "疫情“次生”影响：按下了暂停键的临床试验和CDMO行业",
            "scores": {
                "News_content": "疫情“次生”影响：按下了暂停键的临床试验和CDMO行业",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]